Company: DARE
Filing Date: 2025-12-01
Form Type: 8-K
Source: 0001493152-25-025491
Chunk: 2

Company: Dare Bioscience, Inc.
Filing Date: 2025-12-01
Form: 8-K
Item: Item 7.01
Chunk 2
---
Item      Regulation      

On
December 1, 2025, we issued a press release regarding the matter discussed in Item 1.02, a copy of which is furnished as Exhibit 99.1
to this report.

The
information in this Item 7.01 and in Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended (the “ Securities Act”), whether made before or after the date hereof, regardless
of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference
in such a filing.

  -2-  

Forward
Looking Statements

Daré
cautions you that all statements, other than statements of historical facts, contained in this report, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” “project,” “target,” “objective,” “on track,” or the negative
version of these words and similar expressions. In this report, forward-looking statements include, but are not limited to, statements
relating to our expectation that the termination of the License Agreement will not have a material impact on ongoing pivotal Phase 3
clinical study of Ovaprene and that enrollment in such study will be completed in 2026. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially
different from future results, performance or achievements expressed or implied by the forward-looking statements in this report, including,
without limitation, risks and uncertainties related to: Daré’s ability to design and conduct successful clinical trials,
to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety
concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré’s dependence on third parties,
including